Age-related macular degeneration (AMD) affects an estimated 20 million adults in the United States and is a leading cause of vision loss in people aged 60 and older1 . This progressive eye disease primarily impairs central vision, making everyday tasks such as reading, driving, and recognizing faces challenging2 . While AMD does not cause complete blindness, its impact on quality of life can be profound, especially as the disease advances2 . Treatment and management strategies vary depending on the stage and type of AMD, with ongoing research offering new hope for patients3 .
Treatment by Disease Stage
AMD is classified into early, intermediate, and late stages based on clinical features and disease progression4 . It also presents in two main forms: dry (atrophic) and wet (neovascular), each with distinct pathophysiology and treatment approaches5 . Understanding these stages is crucial for selecting appropriate interventions.
How To Treat Early Dry AMD
Early dry AMD is characterized by the accumulation of drusen—tiny yellow deposits under the macula—detected during fundus examination4 . At this stage, patients are often asymptomatic, and no approved treatments exist to reverse or halt disease progression6 . Management focuses on lifestyle modifications and regular monitoring to delay advancement5 .
Key strategies include:
- Smoking cessation, as smoking is a major modifiable risk factor that accelerates AMD progression4 .
- Adopting a diet rich in antioxidants, omega-3 fatty acids, and leafy green vegetables to support retinal health5 .
- Managing systemic conditions such as hypertension and diabetes to reduce the risk of disease progression4 .
- Scheduling regular ophthalmic evaluations to monitor for changes in retinal status7 .
There is no evidence supporting the use of high-dose antioxidant supplements in early-stage dry AMD, and routine supplementation is not currently recommended at this stage8 .
How To Treat Intermediate Dry AMD
Intermediate dry AMD may present with larger or more numerous drusen and subtle changes in vision, such as mild blurriness or difficulty seeing in low light2 . At this stage, nutritional supplementation with antioxidant vitamins and minerals has been shown to reduce the risk of progression to late AMD8 .
The Age-Related Eye Disease Study 2 (AREDS2) formulation is commonly recommended and includes:
- Vitamin C (500 mg)
- Vitamin E (400 IU)
- Lutein (10 mg)
- Zeaxanthin (2 mg)
- Zinc (80 mg as zinc oxide)
- Copper (2 mg as cupric oxide)
These supplements may help slow vision loss in intermediate AMD but are not beneficial for early-stage disease8 . Patients should continue lifestyle modifications and systemic disease management as in early AMD4 .
Regular eye exams remain essential to detect progression, especially the development of neovascular (wet) AMD, which requires prompt treatment7 .
How To Treat Late-Stage AMD
Late-stage AMD includes advanced dry AMD with geographic atrophy (GA) and wet AMD characterized by abnormal blood vessel growth under the retina5 . These forms cause significant central vision loss and require more intensive management.
Treatment of Wet AMD
Wet AMD accounts for approximately 10–20% of AMD cases but leads to the majority of severe vision loss7 . It results from neovascularization—abnormal blood vessels that leak fluid and blood, causing rapid vision deterioration7 . The mainstay of treatment is intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents, which inhibit abnormal vessel growth and leakage9 5.
Common anti-VEGF drugs include:
| Drug | Notes |
|---|---|
| Ranibizumab | FDA-approved, widely used |
| Aflibercept | Longer duration of action |
| Brolucizumab | Newer agent, may require less frequent dosing |
| Faricimab | Dual action on VEGF and Ang-2 pathways10 |
| Sources: 9510 | |
Anti-VEGF therapy can stabilize vision and sometimes improve it, but frequent injections are often necessary to maintain control10 . Emerging treatments aim to reduce injection frequency through sustained drug delivery systems and gene therapies3 .
Additional therapies include:
- Photodynamic therapy (PDT), which uses a light-activated drug and laser to destroy abnormal vessels11 .
- Laser photocoagulation to seal leaking vessels, though less commonly used due to potential damage to surrounding tissue11 .
Risks of treatment include eye infection, retinal detachment, and cataract progression11 .
Treatment of Late Dry AMD (Geographic Atrophy)
Geographic atrophy is an advanced form of dry AMD marked by the loss of light-sensitive retinal cells, leading to blind spots in central vision12 5. Recent drug approvals target the complement system, a part of the immune response implicated in retinal cell death13 3.
It is important to follow patients regularly so that they understand they have to be monitored for their lifetime. Regular follow-up ensures timely intervention and better outcomes in AMD management14 .
Approved treatments include:
- Pegcetacoplan (Syfovre)
- Avacincaptad pegol (Izervay)
These agents slow the progression of GA but do not restore lost vision13 3.
Other investigational therapies in late-stage trials focus on:
- Inhibiting complement proteins and inflammatory pathways3 .
- Stabilizing mitochondria to reduce cellular stress3 .
- Oral agents for at-home use targeting GA and inherited macular diseases3 .
For some patients with advanced dry AMD, surgical implantation of a telescopic lens may improve both distance and near vision, though it provides a narrow field of view and requires careful patient selection8 .
“I think gene therapy treatments are the game changers that we really want to be able to offer our patients.”
— Adrienne Scott, MD14
Managing Life With Macular Degeneration
Living with AMD involves adapting to progressive vision loss and maintaining quality of life. Central vision impairment affects daily activities such as reading, cooking, and driving, often leading to increased dependency and psychological distress5 6. Patients, especially older adults, are at higher risk for depression and anxiety related to vision loss4 .
Effective management includes:
- Using optical aids such as magnifiers, specialized glasses, and enhanced lighting to improve visual function6 4.
- Employing assistive technologies like digital reading aids and speech recognition software to facilitate communication and access to information5 6.
- Engaging in vision rehabilitation programs to learn skills for independence and adaptation5 2.
- Scheduling regular eye exams and monitoring vision changes with tools like the Amsler grid7 8.
- Maintaining a healthy lifestyle with a plant-based diet, smoking cessation, and control of systemic diseases15 .
Support networks, counseling, and low vision specialists can help patients cope with emotional challenges and adjust to vision changes16 .
Adaptation strategies and assistive technologies play a crucial role in helping AMD patients maintain independence and quality of life. Regular monitoring and lifestyle changes complement medical treatments to slow disease progression and manage symptoms15 45.
Emerging technologies such as electronic retinal implants show promise for restoring vision in patients with advanced geographic atrophy. The Prima device, a microchip implanted under the retina, has enabled some patients to read letters and words again when combined with augmented reality glasses and intensive rehabilitation17 .
Key Points and Summary
- AMD is a progressive retinal disease affecting central vision, classified into dry and wet forms with early, intermediate, and late stages5 4.
- Early dry AMD has no approved treatment but benefits from lifestyle modifications and regular monitoring6 4.
- Intermediate dry AMD may be managed with AREDS2 nutritional supplements to slow progression8 .
- Wet AMD requires intravitreal anti-VEGF injections to inhibit abnormal blood vessel growth and prevent severe vision loss9 5.
- Geographic atrophy, an advanced dry AMD form, can be slowed with newly approved complement-inhibiting drugs13 3.
- Vision rehabilitation, assistive devices, and psychological support are essential for managing daily life with AMD5 616.
- Emerging treatments, including gene therapy and sustained drug delivery, offer hope for improved long-term control14 3.
